Gain-of-Function Research: All in the Eye of the Beholder
Should work done on coronaviruses in Wuhan, China, be considered “gain-of-function” research? Opinions differ.
health
Fauci on COVID Drugs, Vaccines and Getting Back to Normal
The U.S.’s top infectious disease specialist describes a new Biden administration program to develop and test antivirals—and what he’s most worried about as the nation reopens
There Are Few Good COVID Antivirals, but That Could Be Changing
Developing pills that block the novel coronavirus has been challenging. A new Biden administration program aims to boost the effort
COVID-19 long haulers
With the risks of drug development prohibitive, repurposed or repositioned medicines appear the best hope against long-COVID, a condition that still raises many unanswered questions.
New Coronavirus Variants Are Urgently Being Tracked around the World
Genomic sequencing efforts are limited in developing countries, but scientists are mobilizing to help
Lab Leak: A Scientific Debate Mired in Politics — and Unresolved
More than a year into the SARS-CoV-2 pandemic, some scientists say the possibility of a lab leak never got a fair look.